Intracellular bacteria often cause relapsing and refractory infections. However, these infections can be treated effectively with antibiotics such as ofloxacin which penetrate into the cells containing bacteria. As levofloxacin, the levorotatory isomer of ofloxacin, has enhanced antibacterial activity, we tested the levofloxacin concentration in human monocytes and the effects of intracellular levofloxacin on monocyte killing of Staphylococcus aureus strain ATCC 29213 and Pseudomonas aeruginosa strain PA1348A. Human monocytes were incubated with levofloxacin at various pH values and temperatures. Following incubation, the monocytes were separated from incubation media, and intracellular (C) and extracellular (E ) levofloxacin concentrations were determined. Mean C/E ratios after 15 min of incubation with 6 and 12 mg/L levofloxacin at pH 7.4 were 6.4 and 7.1, respectively. C/E ratios were similar at pH 7.4 and 8.0, but decreased at lower pH values. To study the effects of levofloxacin on intracellular killing of S. aureus and P. aeruginosa, opsonized bacteria were added to monolayers of monocytes. Following phagocytosis, monocytes were incubated with various concentrations of levofloxacin, ciprofloxacin and rifampicin, alone or in combination. Levofloxacin (2.5 and 4 mg/L) significantly reduced the survival of cell-associated S. aureus and was more effective than ciprofloxacin at similar concentrations (P < 0.01). Enhanced killing of cell-associated P. aeruginosa by levofloxacin (0.5 and 1.0 mg/L) was also observed. Activities of levofloxacin and ciprofloxacin against cell-associated P. aeruginosa were similar. Addition of rifampicin did not augment the bactericidal activity of levofloxacin. Since levofloxacin is concentrated in human monocytes and increases their bactericidal activity against intracellular bacteria, it should be considered for treatment of infections caused by susceptible intracellular bacteria.
Introduction
Infections caused by intracellular bacterial pathogens are common and frequently cause serious diseases in compromised hosts. These infections may relapse and are difficult to treat unless the antimicrobial agent used has intracellular activity.
1,2 Examples of important infections involving intracellular bacteria include legionellosis, salmonellosis 3 and certain infections caused by Staphylococcus aureus. 4 The importance of using antibiotics with intracellular antibacterial activity has been shown for some of these infections, i.e. legionellosis. 2, 5, 6 Levofloxacin, a fluoroquinolone antibiotic, is the levorotatory component of ofloxacin, a racemic mixture. It is highly active in vitro against Gram-negative and Grampositive bacteria, including Legionella pneumophila, S. aureus, Pseudomonas aeruginosa, salmonellae and others. 7, 8 We studied the ability of human monocytes to concentrate levofloxacin under various conditions of temperature and pH, as well as the effect of levofloxacin on the killing of S. aureus and P. aeruginosa associated with human monocytes. We also compared the effects of levofloxacin, ciprofloxacin and rifampicin (which is often given with fluoroquinolones in the treatment of severe infections) on the bactericidal activity of human monocytes. 
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Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa
Preparation of monocytes
Monocytes were isolated from the heparinized blood of healthy human donors by centrifugation using Histopaque 1077 (Sigma Chemical Co.). The cells were tested for viability using the trypan blue exclusion test, counted and resuspended at a final concentration of 10 7 cells/mL in either Hanks' balanced salt solution without Ca 2ϩ or Mg (HBSS) (for drug uptake studies) or HBSS ϩ 10% fetal calf serum (for bactericidal studies). The separated monocytes were resuspended at the appropriate pH values and temperatures in individual experiments as described below.
Concentration of levofloxacin in human monocytes
The ability of human monocytes to concentrate levofloxacin was tested at extracellular levofloxacin concentrations of 6 and 12 mg/L. The effects of temperature were tested at pH 7.4 and temperatures of 4, 37 and 42°C. The effects of pH were tested at 37°C and pH 4.0, 5.0 and 8.0. Treated monocytes were separated from the incubation medium after 2, 5, 10 and 20 min by velocity gradient centrifugation through silicon oil (Dow-Corning, Corning, NY, USA) at 12 000g. 10 The resulting monocyte pellets were then resuspended in 2 mL of 0.1 M glycine buffer, pH 3.0 and incubated for 2 h at room temperature in order to lyse the cells. The lysate was then centrifuged at 10 000g to remove cell debris. Intracellular (from the cleared lysate) and extracellular (from the incubation medium remaining on top of the silicon oil) levofloxacin concentrations were then measured by fluorescence spectroscopy 10 using an SP Model 500C Fluorometer (SLM Aminco, Inc., St Louis, MO, USA) at excitation and emission wavelengths of 262 and 496 nm, respectively. Levofloxacin concentrations were expressed as C/E ratios, where C is the intracellular concentration and E is the extracellular concentration. For each experiment, the total cellular volume and volume of cell-associated extracellular water were determined using 3 H-labelled water and 14 C-labelled polyethylene glycol as described previously. 10 
Bactericidal assays
Bacteria were grown overnight in Mueller-Hinton (MH) broth (BBL, Cockeysville, MD, USA). Following centrifugation of the broth culture at 2000g for 15 min, the resulting bacterial pellet was resuspended in HBSS. Bacteria were then opsonized for 60 min at 37°C with constant agitation using 20% pooled, heat-inactivated normal human serum. Following opsonization, the bacteria were washed and resuspended in HBSS at a final concentration of 1 ϫ 10 7 cfu/mL and held at 4°C until use. Using a 10:1 ratio of opsonized bacteria to monocytes and appropriate concentrations of levofloxacin, ciprofloxacin and rifampicin, samples were incubated at 37°C on a rotator at 10 rpm. Sampling times were 0, 1, 2, 3, 4 and 24 h for P. aeruginosa and 0, 20, 45, 90 and 180 min, and 24 h for S. aureus. Samples (100 L) were diluted in 2.5 mL of phosphate-buffered saline (PBS) and centrifuged for 5 min at 160g. The resulting pellets were washed twice in PBS using 2.5 mL each time. Monocytes were lysed with distilled water. Serially diluted 25 L samples were plated on MH agar plates (BBL). Colonies were counted after plates had been incubated overnight at 37°C. These cell-associated bacteria are reported as cfu/mL. The percentage of viable counts ϭ (geometric mean cfu/mL at each time point/geometric mean cfu/mL at time 0) ϫ100.
Statistical analysis
Statistical analyses of the results of the monocyte bactericidal assays were performed using log 10 of the cfu/mL and analysis of variance. 11 The level of significance was 0.05.
Results
Intracellular concentration of levofloxacin
Levofloxacin concentrations within viable human monocytes were in the range 18-40 mg/L, and were up to six times the extracellular concentration following incubation for 15 min at pH 7.4 and 37°C. Peak concentrations were reached in 5 to 15 min (Figure 1 ). The intracellular levofloxacin concentration following incubation at pH 4 or 5 (data combined for pH 4 and 5) was lower than at pH 7.4. At pH 8.0 the intracellular levofloxacin concentration was similar to that at pH 7.4 ( Figure 1 ). Figure 1 shows the effect of temperature on levofloxacin uptake by human monocytes. During the first 10 min of incubation the intracellular levofloxacin concentration rose more rapidly at 42°C than at 37°C. However, at 42°C the intracellular concentration decreased after 10 min, while at 37°C it continued to rise. After 15 min the intracellular levofloxacin concentrations at 37°C and 42°C were similar. In contrast, at 4°C and pH 7.4 the intracellular and extracellular levofloxacin concentrations were similar, suggesting that little if any drug penetration into monocytes had occurred at that temperature. Complete washout of levofloxacin from monocytes occurred within 2 to 5 min following removal of the drug from the incubation medium (data not shown).
Bactericidal activity in human monocytes
The intracellular antibacterial activities of levofloxacin and ciprofloxacin were studied singly and in combination with rifampicin. Activities against P. aeruginosa strain PA1348A and S. aureus strain ATCC 29213 were determined. The intracellular activities of levofloxacin and ciprofloxacin against P. aeruginosa strain PA1348A were both concentration and time dependent (Figure 2 ). The killing rates of effective doses were greatest during the first hour for both drugs, but maximum killing and differences among doses were seen at 3-4 h for all concentrations tested (P Ͻ 0.01). Figure 2 shows the activities of levofloxacin and ciprofloxacin against P. aeruginosa strain PA1348A singly at 1 ϫ MIC (0.5 mg/L of levofloxacin, 0.125 mg/L of cipro- floxacin) and in combination with rifampicin (8 mg/L). When tested individually, all three drugs showed rapid antibacterial activity at 1 h, with maximum total activity at 3-4 h. The differences in the activities of either levofloxacin or ciprofloxacin when used in combination with rifampicin were not statistically significant. The percentage of bacterial survival at 24 h was 0.2-0.6% for each of the three drugs and for the combinations. Figure 3 shows the intracellular activity of levofloxacin against S. aureus strain ATCC 29213. After 20 min at 2.5 and 4 mg/L (average and high concentrations achievable in human serum) the differences in survival percentages between the treated and untreated cells were not statistically significant. However, at both 45 and 90 min the bacterial survival percentages were significantly lower than those of the controls (P Ͻ 0.01). There was no significant difference in bacterial survival between the two drug concentrations. When levofloxacin, ciprofloxacin and rifampicin were tested individually against S. aureus strain ATCC 29213 at concentrations achievable in human serum (Figure 3) , rifampicin demonstrated the greatest antibacterial activity after 45 min of incubation. However, there was no significant difference in the survival of ciprofloxacintreated and control cells. At 90 min of exposure, all three drugs exhibited antibacterial activity, with rifampicin and levofloxacin more effective than ciprofloxacin (P Ͻ 0.01). At 180 min, levofloxacin had significantly greater antibacterial activity than ciprofloxacin or rifampicin alone or either fluoroquinolone in combination with rifampicin (P Ͻ 0.05). Survival at 24 h was Ͻ5% for cells treated with levofloxacin or ciprofloxacin alone or in combination with rifampicin.
Discussion
A variety of antimicrobial agents, including macrolides, ketolides, lincosamines, rifamycins and fluoroquinolones, are known to be concentrated inside mammalian phagocytes, reaching greater intracellular concentrations than their extracellular concentrations. 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Because of their bactericidal activities against both Gram-positive and Gramnegative intracellular pathogens the fluoroquinolones are potentially the most important of these agents.
The uptake kinetics and intracellular concentrations of levofloxacin in human monocytes found in this study are similar to those reported for ciprofloxacin. 16, 27 Our study indicates that intracellular concentrations of levofloxacin in monocytes are also similar to those found in polymorphonuclear leucocytes (PMNs). 28 Several fluoroquinolone antibiotics have been shown to penetrate and be concentrated in human PMNs, 10, 17, 18, 22, 25, 27 ,28 macrophages 22, 29 and monocytes. 26 In previous studies of the ability of human phagocytic cells to concentrate fluoroquinolones, a range of four-fold to Ͼ40-fold concentration has been observed. 10, 14, 17, 18, 22, 25, 26, 28, 29 Methodological differences, including source of cells, type of cells and detection assays, could account for some of the differences among the drugs tested. For fluoroquinolones in general, there appear to be no energy-dependent mechanisms that determine intracellular drug concentrations. 30 For most of the fluoroquinolones studied to date, elution of drug from phagocytic cells is rapid following removal of the drug from the extracellular environment. 28 However, one study showed that fluoroquinolones are more readily retained by phagocytic cells containing ingested L. pneumophila than by the same cells in the absence of ingested bacteria. 13 This suggests fluoroquinolone trapping in the presence of ingested bacteria that have escaped from phagolysosomes. When studied with PMNs and measured by the same method used in our studies 10 levofloxacin reached intracellular concentrations approximately six times the extracellular concentration. 28 The responses to lowered temperature and changes in pH were similar to those seen with other fluoroquinolones. 28 Studies have suggested that fluoroquinolones, including levofloxacin, are taken up more slowly by human macrophages than by PMNs. 22 However, some of these studies have used mononuclear cells harvested from peritoneal dialysate and the effect of this medium on cell behaviour is not known.
The role of antibacterial activity within phagocytic cells and the outcome of experimental and clinical infections are well established, especially for infections caused by L. pneumophila. 8, 29 However, relatively little is known about the augmentation of intracellular bacterial killing by human monocytes. Antibacterial activity in phagocytic cells depends upon the intracellular site of drug localization (which is unknown for fluoroquinolones) relative to the intracellular location of the bacteria, the stability of the drug in the intracellular environment and the susceptibility of the microorganism to the drug while within the cell. The latter can vary with the metabolic activity or growth rate of the ingested organism. The present study provided evidence that the rate and degree of intracellular killing of P. aeruginosa are affected equally by levofloxacin and ciprofloxacin at concentrations with equivalent effectiveness (reflected in the MICs of the individual drugs).
Because of concern that S. aureus will develop resistance when exposed to low (sub-MIC) concentrations of fluoroquinolones, we studied the effects of levofloxacin and ciprofloxacin at (extracellular) concentrations similar to achievable serum concentrations. Since rifampicin has been shown to be the most active agent against intraphagocytic staphylococci, 26 we included rifampicin both as a comparative agent and to investigate its possible additive or antagonistic effects in combination with each of the fluoroquinolones studied. There was no dose effect for levofloxacin, but levofloxacin caused significant killing of intracellular S. aureus after as little as 45 min incubation. Although ciprofloxacin was active against S. aureus by 180 min of incubation, levofloxacin demonstrated the best activity, even when compared with rifampicin alone. When compared with the individual fluoroquinolones alone, addition of rifampicin to either fluoroquinolone did not increase bacterial killing. This suggests that the antibacterial activity of levofloxacin against S. aureus is greater than that of rifampicin in the intracellular environment.
Previous studies with S. aureus have shown that drugs with a very high degree of penetration into phagocytic cells, such as erythromycin, clarithromycin, azithromycin, roxithromycin and clindamycin, act in an inhibitory but not bactericidal fashion in experiments lasting up to 24 h. 12, 15, 19, 21, 24, 26, 31 At appropriate concentrations ciprofloxacin has been shown to enhance the activity of phagocytic cells in killing S. aureus. 16 Our study demonstrates the rapid bactericidal activity of levofloxacin against both P. aeruginosa and S. aureus. The activity of levofloxacin against P. aeruginosa was equivalent to that of ciprofloxacin, the most active anti-pseudomonal fluoroquinolone in current clinical use. In contrast, levofloxacin was more active than ciprofloxacin against S. aureus.
Levofloxacin remains in human mononuclear phagocytes as long as extracellular levofloxacin is present, and reaches concentrations within the cells approximately sixfold greater than the external concentration. More importantly, the presence of levofloxacin enhances the ability of human monocytes to kill both S. aureus and P. aeruginosa, two organisms that can persist inside mammalian cells. Since other antibacterial agents either lack bactericidal capability or do not reach adequate concentrations within phagocytes, levofloxacin offers an advantage in the treatment of serious infections caused by microorganisms that can persist inside phagocytic cells.
